The genome editing market was valued at US$ 3,210.1 in 2017 and is expected to reach US$ 10,691.0 Mn in 2025. The market is estimated to grow with a CAGR of 17.0% from 2017-2025.
The report includes the driving factors such as increase in funding for the genome editing, rising prevalence of the genetic disorders, rise in the advancements for the genome editing technology and rise in the production of the genetically modified crops. The opportunities for the market is analyzed as the emerging markets for precision and regenerative medicines. The usage of CRISOR Cas9 technology is the current for the genome editing market.
In our study of genome editing market, the segmentation is done into three major segments such as technology, application, and end user. The technology segment is divided into transcription activator-like effector nucleases (TALENS), clustered regularly interspaced short palindromic repeats (CRIPSR), zinger finger nuclease (ZFNs), antisense RNA and others. The application segment consists of genetic engineering, cell line engineering and others. The genetic engineering is further divided into animal genetic engineering and plant genetic engineering. Similarly, the end user is classified as biotechnology & pharmaceutical companies, contract research organization, academic & government research organization and other end users.
Key industry players operating in the field of genome editing across the globe include Transposagen Biopharmaceuticals, Inc., Integrated DNA Technologies, Inc., Thermo Fisher Scientific Inc., GenScript, Lonza, Horizon Discovery Group plc, Sangamo Therapeutics, Inc., New England Biolabs, Editas Medicine, Merck KGaA.
The technology segment is divided into transcription activator-like effector nucleases (TALENS), clustered regularly interspaced short palindromic repeats (CRISPR), zinc finger nucleases (ZFNs), antisense RNA and others. Among the technology segment the CRISPR holds the largest market share whereas, the TALENs is the fastest growing segment. The dominancy is expected to be continued by the CRISPR owing to the advantages offered, elimination of invading genetic material and enables the organisms to respond the changes. In addition, CRISPR-Cas9 is faster, cheaper and more accurate than the other technologies of DNA editing and is used for the wide applications. It is considered to be the simplest, most versatile and precise method of genetic manipulation. Moreover, the CRISPR technology is utilized in every field of the genome editing. The market for genome editing by the technology segment is expected to reach US$ 6,132.3 million by 2025 in the forecasted period. CRISPR segment has the highest market share in 2017, contributing a market share of 53.6% and is expected to retain its dominance during the forecast period from 2018 to 2025 to account for a market share of 57.4% of the overall revenue generated in 2025.
The objective or the scope the study was defining, describing, and forecasting the genome editing market on the basis of technology, application, end user and region. In addition, analyzing the market structure, profiling the key players of the market, and comprehensively analyzing their core competencies. Tracking and analyzing competitive developments such as new product launches; market consolidations and clinical trials and other developments in the genome editing market. Moreover, the aim of the study was providing detailed information regarding the major factors or the reasons that are influencing the growth of the market in the five major regions such as North America, Europe, Asia Pacific, Middle East and Africa and South and Central America.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.